cardioКардиологияKardiologiia0022-90402412-5660Kardiomag10.18087/cardio.2422cardio-90Research ArticleОБЗОРЫREVIEWSВопросы антитромботической терапии у пациентов с фибрилляцией предсердий, перенесших ОКСIssues of antithrombotic therapy in ACS patients with atrial fibrillationКайдаловаН. А.KaydalovaN. A.noemail@neicon.ruКоролеваЛ. Ю.KorolevaL. Yu.noemail@neicon.ruКовалеваГ. В.KovalevaG. V.noemail@neicon.ruПайковаН. Н.PaykovaN. N.noemail@neicon.ruНосовВ. П.NosovV. P.noemail@neicon.ruВолковаА. Т.VolkovaA. T.noemail@neicon.ruКорязинаА. М.KoryazinaA. M.noemail@neicon.ruФГБОУ ВО «НижГМА» МЗ РФРоссияNizhny Novgorod State Medical Academy, Minin and PozharskyRussian FederationГБУЗ НО «НОКБ им. Н.А. Семашко»РоссияNizhny Novgorod Regional Clinical Hospital named after N.A. SemashkoRussian Federation201818112018581S2230Copyright © Kardiomag, 20182018KardiomagKardiomaghttps://cardio.elpub.ru/jour/about/submissions#copyrightNoticehttps://cardio.elpub.ru/jour/article/view/90

В обзорной статье проанализированы современные представления о распространенности и клинической значимости фибрилляции предсердий у пациентов, перенесших острый коронарный синдром, описаны существующие подходы к назначению антитромботической терапии, отражены имеющиеся клинические исследования по применению варфарина и новых пероральных антикоагулянтов в составе комбинированной антитромботической терапии у пациентов с фибрилляцией предсердий и острым коронарным синдромом.

The review analyzed current ideas on prevalence and clinical significance of atrial fibrillation following acute coronary syndrome; described modern approaches to administration of antithrombotic therapy; and addressed available clinical studies on the treatment with warfarin and new oral anticoagulants as a part of combination antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome.

фибрилляция предсердийострый коронарный синдромантитромботическая терапиятройная антитромботическая терапияновые пероральные антикоагулянтыварфариндабигатранривароксабанапиксабанatrial fibrillationacute coronary syndromeantithrombotic therapytriple antithrombotic therapynew oral anticoagulantswarfarindabigatranrivaroxabanapixabanReferencesМоисеев С. В., Киякбаев Г. Г., Фомин В. В. Антитромботическая терапия у больных с фибрилляцией предсердий, перенесших ОКС. Клиническая фармакология и терапия. 2014;23(3):39-44. [Moiseev S.V., Kyakbaev G.G., Fomin V.V. Antithrombotic treatment in patientswith atrial fibrillation after acute coronary syndrome. Clinical pharmacology and therapy. 2014;23(3):39-44.]Моисеев С. В., Киякбаев Г. Г., Фомин В. В. Антитромботическая терапия у больных с фибрилляцией предсердий, перенесших ОКС. Клиническая фармакология и терапия. 2014;23(3):39-44. [Moiseev S.V., Kyakbaev G.G., Fomin V.V. Antithrombotic treatment in patientswith atrial fibrillation after acute coronary syndrome. Clinical pharmacology and therapy. 2014;23(3):39-44.]ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949-3003. D0I:10.1093/eurheartj/ eht296ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal. 2013;34(38):2949-3003. D0I:10.1093/eurheartj/ eht296Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. D0I:10.1093/europace/euw295Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609-78. D0I:10.1093/europace/euw295GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. D0I:10.1016/S0140-6736(14)61682-2GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-71. D0I:10.1016/S0140-6736(14)61682-2Шляхто Е. В. Кардиология. Национальное руководство. -М.: ГЭОТАР-Медиа; 2015. 800 с.Шляхто Е. В. Кардиология. Национальное руководство. -М.: ГЭОТАР-Медиа; 2015. 800 с.Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - Double trouble. Adv Med Sci. 2017;63(1):30-5. D0I:10.1016/j.advms.2017.06.005Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J. Patients with atrial fibrillation and coronary artery disease - Double trouble. Adv Med Sci. 2017;63(1):30-5. D0I:10.1016/j.advms.2017.06.005Almendro-Delia M, Valle-Caballero MJ, Garcia-Rubira JC, Munoz-Calero B, Garcia-Alcantara A, Reina-Toral A et al. Prognostic impact of atrial fibrillation in acute coronary syndromes: results from the ARIAM registry. Eur Heart J Acute Cardiovasc Care. 2014;3(2):141-8. D0I:10.1177/2048872613517370Almendro-Delia M, Valle-Caballero MJ, Garcia-Rubira JC, Munoz-Calero B, Garcia-Alcantara A, Reina-Toral A et al. Prognostic impact of atrial fibrillation in acute coronary syndromes: results from the ARIAM registry. Eur Heart J Acute Cardiovasc Care. 2014;3(2):141-8. D0I:10.1177/2048872613517370McManus DD, Huang W, Domakonda KV, Ward J, Saczysnki JS, Gore JM et al. Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome. Am J Med. 2012; 125 (l l): 1076 84. DOI: 10.1016/j.amjmed.2012.05.024McManus DD, Huang W, Domakonda KV, Ward J, Saczysnki JS, Gore JM et al. Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome. Am J Med. 2012; 125 (l l): 1076 84. DOI: 10.1016/j.amjmed.2012.05.024Lopes RD, White JA, Atar D, Keltai M, Kleiman NS, White HD, et al. Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2013;168(3):2510-7. D01:10.1/016/j. ijcard.2013.03.037Lopes RD, White JA, Atar D, Keltai M, Kleiman NS, White HD, et al. Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. Int J Cardiol. 2013;168(3):2510-7. D01:10.1/016/j. ijcard.2013.03.037Тарловская Е.И., Дорофеева Ю. A., Мальчикова C. В. Ретроспективный анализ клинического статуса пациентов с фибрилляцией предсердий, предшествующего ОКС: данные локального регистра. Сердце: журнал для практикующих врачей. 2017; 16 (4):235-45. [Tarlovskaya E. I., Dorofeeva J. A., Malcikova S. V. Retrospective analysis of the clinical status of patients with atrial fibrillation preceding acute coronary syndrome: Local register data. Russian Heart Journal. 2017;16(4):235-245]Тарловская Е.И., Дорофеева Ю. A., Мальчикова C. В. Ретроспективный анализ клинического статуса пациентов с фибрилляцией предсердий, предшествующего ОКС: данные локального регистра. Сердце: журнал для практикующих врачей. 2017; 16 (4):235-45. [Tarlovskaya E. I., Dorofeeva J. A., Malcikova S. V. Retrospective analysis of the clinical status of patients with atrial fibrillation preceding acute coronary syndrome: Local register data. Russian Heart Journal. 2017;16(4):235-245]Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer С et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(l9):2411-20. PMID:12435254Steinhubl SR, Berger PB, Mann JT, Fry ETA, DeLago A, Wilmer С et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(l9):2411-20. PMID:12435254Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-21. D01:10.1016/S0140-6736(05)67660-XChen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005;366(9497):1607-21. D01:10.1016/S0140-6736(05)67660-XСулимов В. A., Голицын С. П., Панченко Е. П., Попов С. В., Ревишвили А. Ш., Шубик Ю. В. и др. Диагностика и лечение фибрилляций предсердий. Рекомендации РКО, ВНОА И АССХ. Российский кардиологический журнал. 2013;4 S3:1-100. [SulimovV. A., Golitsin S. P., Panchenko E. Р., PopovS. V., Revishvili A. Sh., Shubik Yu. V. et al. Diagnosis and treatment of atrial fibrillation. Recommendations of RSC, RSSA and ACVS. RussJ Cardiol. 2013;4(S3):1-100.]Сулимов В. A., Голицын С. П., Панченко Е. П., Попов С. В., Ревишвили А. Ш., Шубик Ю. В. и др. Диагностика и лечение фибрилляций предсердий. Рекомендации РКО, ВНОА И АССХ. Российский кардиологический журнал. 2013;4 S3:1-100. [SulimovV. A., Golitsin S. P., Panchenko E. Р., PopovS. V., Revishvili A. Sh., Shubik Yu. V. et al. Diagnosis and treatment of atrial fibrillation. Recommendations of RSC, RSSA and ACVS. RussJ Cardiol. 2013;4(S3):1-100.]Thompson PL, Verheugt F WA. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Clin Ther.2014;36(9):l 176-81. D01:10.1016/j.clinthera.2014.08.010Thompson PL, Verheugt F WA. Managing antithrombotic therapy in patients with both atrial fibrillation and coronary heart disease. Clin Ther.2014;36(9):l 176-81. D01:10.1016/j.clinthera.2014.08.010Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329) :71-86. PMID: 11786451Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329) :71-86. PMID: 11786451Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;5l(8):818-25. D01:10.1016/ j.jacc.2007.11.035Ruiz-Nodar JM, Marin F, Hurtado JA, Valencia J, Pinar E, Pineda J et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008;5l(8):818-25. D01:10.1016/ j.jacc.2007.11.035Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen M-A et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28(6):726-32. D01:10.1093/eurheartj/ehl488Karjalainen PP, Porela P, Ylitalo A, Vikman S, Nyman K, Vaittinen M-A et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007;28(6):726-32. D01:10.1093/eurheartj/ehl488Козиолова H.A., Суровцева М. В. Подходы к выбору антикоагулянтной терапии у больных с неклапанной фибрилляцией предсердий и ИБС. Кардиоваскулярная терапия ипрофилактика. 2016; 15 (2):83-92. [Koziolova N. A., Surovtseva М. V. Approaches to anticoagulation therapy selection in patients with non-valvular atrial fibrillation and ischemic heart disease. Cardiovascular therapy and prevention. 2016; 15 (2) :83-92.]Козиолова H.A., Суровцева М. В. Подходы к выбору антикоагулянтной терапии у больных с неклапанной фибрилляцией предсердий и ИБС. Кардиоваскулярная терапия ипрофилактика. 2016; 15 (2):83-92. [Koziolova N. A., Surovtseva М. V. Approaches to anticoagulation therapy selection in patients with non-valvular atrial fibrillation and ischemic heart disease. Cardiovascular therapy and prevention. 2016; 15 (2) :83-92.]Paikin JS, Wright D S, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;12l(l8):2067-70. D OI: 10.1161 /CIRCUL ATIONAHA. 109.924944Paikin JS, Wright D S, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010;12l(l8):2067-70. D OI: 10.1161 /CIRCUL ATIONAHA. 109.924944Bousser M-G. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 3:12-9. D01:10.1159/ 000209261Bousser M-G. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 3:12-9. D01:10.1159/ 000209261Baker WL, Cios DA, Sander SD, Coleman CL Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244-52. D01:10.18553/jmcp.2009.15.3.244Baker WL, Cios DA, Sander SD, Coleman CL Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. J Manag Care Pharm. 2009;15(3):244-52. D01:10.18553/jmcp.2009.15.3.244Pam Harrison. Low Adherence to All 0ral Anticoagulants the Norm in Atrial Fib [Интернет]. 2016мар8 [цитируется по 29 январь 2018 г.]Pam Harrison. Low Adherence to All 0ral Anticoagulants the Norm in Atrial Fib [Интернет]. 2016мар8 [цитируется по 29 январь 2018 г.]Королева Л. Ю., Носов В. П., Колесниченко И. В., Злобин М. В., Абелев Д. И. Возможности антикоагулянтной терапии у пациентов с фибрилляцией предсердий: ривароксабан и варфарин. Рациональная фармакотерапия в кардиологии. 2016;12(5):553 7. [Koroleva I.Y., Kolesnichenko I.V., Nosov V.P., Zlobin M.V., Abelevich D.I. The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin. Rational Pharmacotherapy in Cardiology. 2016;12 (5):553-557.] D0I:10.20996/1819-6446-2016-12-5-553-557Королева Л. Ю., Носов В. П., Колесниченко И. В., Злобин М. В., Абелев Д. И. Возможности антикоагулянтной терапии у пациентов с фибрилляцией предсердий: ривароксабан и варфарин. Рациональная фармакотерапия в кардиологии. 2016;12(5):553 7. [Koroleva I.Y., Kolesnichenko I.V., Nosov V.P., Zlobin M.V., Abelevich D.I. The Anticoagulation in Patients with Atrial Fibrillation: Rivaroxaban and Warfarin. Rational Pharmacotherapy in Cardiology. 2016;12 (5):553-557.] D0I:10.20996/1819-6446-2016-12-5-553-557Potpara TS, Lane DA, Lip GYH. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace. 2015;17(4):507-8. D0I:10.1093/europace/euv041Potpara TS, Lane DA, Lip GYH. Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. Europace. 2015;17(4):507-8. D0I:10.1093/europace/euv041Барбараш О. Л., Кашталап В. В. Подходы к рациональной антитромботической терапии у пациентов с ОКС и неклапанной фибрилляцией предсердий (по материалам Европейского конгресса кардиологов, 2014). Consilium Medicum. 2015;17(5): 49-53. [Barbarash 0.L., Kashtalap VV. Rational approaches to antithrombotic therapy in patients with acute coronary syndromes and non-valvular atrial fibrillation (adapted from the European Congress of Cardiology 2014). Consilium medicum. 2015;17(5):49-53.]Барбараш О. Л., Кашталап В. В. Подходы к рациональной антитромботической терапии у пациентов с ОКС и неклапанной фибрилляцией предсердий (по материалам Европейского конгресса кардиологов, 2014). Consilium Medicum. 2015;17(5): 49-53. [Barbarash 0.L., Kashtalap VV. Rational approaches to antithrombotic therapy in patients with acute coronary syndromes and non-valvular atrial fibrillation (adapted from the European Congress of Cardiology 2014). Consilium medicum. 2015;17(5):49-53.]Dewilde WJM, 0irbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. D0I:10.1016/ S0140-6736(12)62177-1Dewilde WJM, 0irbans T, Verheugt FWA, Kelder JC, De Smet BJGL, Herrman J-P et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107-15. D0I:10.1016/ S0140-6736(12)62177-1Fox KAA. Dual or single antiplatelet therapy with anticoagulation? Lancet. 2013;381(9872): 1080-1. D0I:10.1016/S0140-6736(13)60054-9Fox KAA. Dual or single antiplatelet therapy with anticoagulation? Lancet. 2013;381(9872): 1080-1. D0I:10.1016/S0140-6736(13)60054-9R0CKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the R0CKET AF study. Am Heart J. 2010;159(3):340-347.e1. D0I:10.1016/j.ahj.2009.11.025R0CKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the R0CKET AF study. Am Heart J. 2010;159(3):340-347.e1. D0I:10.1016/j.ahj.2009.11.025Jeffrey S. New Strategies for AF Patients Undergoing PCI Cut Bleeding [Интернет]. medscape.com. 2016 [цитируется по 29 январь 2018 г.].Jeffrey S. New Strategies for AF Patients Undergoing PCI Cut Bleeding [Интернет]. medscape.com. 2016 [цитируется по 29 январь 2018 г.].Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, 0ldgren J, Reilly PA et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELYABLE) study. Circulation. 2013;128(3):237-43. D0I:10.1161/ CIRCULATIONAHA.112.001139Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, 0ldgren J, Reilly PA et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (RELYABLE) study. Circulation. 2013;128(3):237-43. D0I:10.1161/ CIRCULATIONAHA.112.001139Cannon CP, Bhatt DL, 0ldgren J, Lip GYH, Ellis SG, Kimura T et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-24. D0I:10.1056/ NEJMoa1708454Cannon CP, Bhatt DL, 0ldgren J, Lip GYH, Ellis SG, Kimura T et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513-24. D0I:10.1056/ NEJMoa1708454Напалков Д. А., Соколова А. А., Родионов А. В. Фибрилляция предсердий и ИБС: как сочетать антиагрегантную и антикоагулянтную терапию в зависимости от клинической ситуации? Рациональная фармакотерапия в кардиологии. 2016; 12(2): 191-5. [Napalkov D.A., Sokolova A.A., Rodionov A.V. Atrial fibrillation and ischemic heart disease: how to combine antiplatelet and anticoagulant therapy, depending on the clinical situation? Rational Pharmacotherapy in Cardiology. 2016;12(2):191-195.] D0I:10.20996/1819-6446-2016-12-2-191-195Напалков Д. А., Соколова А. А., Родионов А. В. Фибрилляция предсердий и ИБС: как сочетать антиагрегантную и антикоагулянтную терапию в зависимости от клинической ситуации? Рациональная фармакотерапия в кардиологии. 2016; 12(2): 191-5. [Napalkov D.A., Sokolova A.A., Rodionov A.V. Atrial fibrillation and ischemic heart disease: how to combine antiplatelet and anticoagulant therapy, depending on the clinical situation? Rational Pharmacotherapy in Cardiology. 2016;12(2):191-195.] D0I:10.20996/1819-6446-2016-12-2-191-195Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a NorthAmerican perspective: executive summary. Circ Cardiovasc Interv. 2011;4(5):522 34. D0I:10.1161/CIRCINTERVENTI0NS.111.965186Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: a NorthAmerican perspective: executive summary. Circ Cardiovasc Interv. 2011;4(5):522 34. D0I:10.1161/CIRCINTERVENTI0NS.111.965186Angiolillo DJ, Gibson CM, Cheng S, 0llier C, Nicolas O, Bergougnan L et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. D0I:10.1038/clpt.2010.219Angiolillo DJ, Gibson CM, Cheng S, 0llier C, Nicolas O, Bergougnan L et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011;89(1):65-74. D0I:10.1038/clpt.2010.219Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619-33. D0I:10.1161/ CIR.0b013e318202f701Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation. 2010;122(24):2619-33. D0I:10.1161/ CIR.0b013e318202f701Фонякин А. В. К 5-летию клинического применения новых пероральных антикоагулянтов при неклапанной фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2015;7(2):4-9. [Fonyakin A.V. The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(2):4-9.] D0I:10.14412/2074-2711-2015-2-4-9Фонякин А. В. К 5-летию клинического применения новых пероральных антикоагулянтов при неклапанной фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2015;7(2):4-9. [Fonyakin A.V. The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation. Neurology, Neuropsychiatry, Psychosomatics. 2015;7(2):4-9.] D0I:10.14412/2074-2711-2015-2-4-9Glund S, Stangier J, Schmohl M, Smet MD, Gansser D, Lang B, et al. Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers. Circulation. 2013;128(Suppl 22):A17765-A17765.Glund S, Stangier J, Schmohl M, Smet MD, Gansser D, Lang B, et al. Abstract 17765: A Specific Antidote for Dabigatran: Immediate, Complete and Sustained Reversal of Dabigatran Induced Anticoagulation in Healthy Male Volunteers. Circulation. 2013;128(Suppl 22):A17765-A17765.Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. D0I:10.1002/14651858. CD000011.pub3Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008;(2):CD000011. D0I:10.1002/14651858. CD000011.pub3Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-33. PMID:19514806Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care. 2009;15(6):e22-33. PMID:19514806Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res 0pin. 2012;28(5):669-80. D0I: 10.1185/03007995.2012.677419Coleman CI, Roberts MS, Sobieraj DM, Lee S, Alam T, Kaur R. Effect of dosing frequency on chronic cardiovascular disease medication adherence. Curr Med Res 0pin. 2012;28(5):669-80. D0I: 10.1185/03007995.2012.677419

The authors declare that there are no conflicts of interest present.